Patent number: 12384850
Abstract: The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
August 12, 2025
Assignee:
SYSTIMMUNE, INC.
Inventors:
Yi Zhu, Ole Olsen, Dong Xia, David Jellyman, Katrina Bykova, Anne-Marie K. Rousseau, Bill Brady, Blair Renshaw, Brian Kovacevich, Yu Liang, Camilla Wang, Zeren Gao